AIFF
Firefly Neuroscience, Inc.1.4100
-0.0600-4.08%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
19.03MP/E (TTM)
-Basic EPS (TTM)
-2.26Dividend Yield
0%Recent Filings
8-K
Terminates ELOC, boosts CFO pay
Firefly Neuroscience terminated its $10 million equity line of credit agreement with Arena Business Solutions, effective September 11, 2025, after entering it in December 2024. Meanwhile, the board approved a salary hike for CFO Paul Krzywicki from CA$165,000 to CA$216,000 starting September 1, 2025. Termination simplifies capital access. No further impacts disclosed.
10-Q
Q2 FY2025 results
Firefly Neuroscience posted Q2 revenue of $299 thousand, up sharply from $10 thousand a year ago, thanks to the Evoke acquisition that kicked in late April. Gross margin hit 91.7%, but operating loss widened to $1.6 million from $1.3 million amid higher general and admin costs from integration. For the half, revenue reached $342 thousand versus $22 thousand last year, while operating loss climbed to $3.7 million; net loss ballooned to $14.8 million from $2.4 million, driven by a $9.4 million derivative fair value hit and $1.4 million settlement loss on debt conversion. Cash swelled to $5.9 million on $11.4 million in equity raises, funding the $3 million cash Evoke deal that added $5.2 million goodwill and $1.0 million intangibles amortized over 3-9 years. Evoke delivered $251 thousand revenue post-close. Warrants pack a dilutive punch.
8-K
Firefly raises $1.2M via units
Firefly Neuroscience closed a $1.2 million private placement on June 16, 2025, issuing 400,000 units at $3.00 each to accredited investors, including shares or pre-funded warrants plus five-year warrants exercisable at $3.50 and $4.00 per share. The deal bolsters working capital amid neuroscience development, yet dilutes existing shareholders with a 4.99% ownership cap. Proceeds fuel general operations.
10-Q
Q1 FY2025 results
Firefly Neuroscience posted Q1 revenue of $43, up 258% y/y from $12, driven by more customers and BNA scans, yet operating loss widened to $2.1M from $1.1M on higher general and administrative costs. Net loss ballooned to $12.9M from $1.1M, with the gap to operating loss mainly from a $9.4M derivative fair value change and $1.4M note settlement loss. Cash climbed to $9.5M, fueled by $10.3M in financing from warrant exercises and a private placement, while operating cash burn hit $2.5M. Post-quarter, it closed the Evoke acquisition in April 2025 for $6M (half cash, half stock) plus up to $0.5M contingent, aiming to bolster brain measurement tech. Diluted EPS of -$1.74 aligns with weighted shares of 9.96M; anti-dilution excluded 1.8M potential shares. Cash position strengthens runway. Regulatory hurdles could slow commercialization.
8-K
Firefly acquires Evoke Neuroscience
Firefly Neuroscience acquired Evoke Neuroscience on May 1, 2025, for $3 million cash and $3 million in common stock at $3.50 per share, plus a $500,000 earn-out in stock if Evoke hits $3 million annualized revenue within 36 months. This deal triples Firefly's patents to 27 and expands its EEG/ERP database over two-fold to more than 180,000 records, while boosting commercial users ten-fold to over 60 sites. Integration promises faster AI-driven brain health insights. Yet working capital shortfalls could trim the cash payout.
ALIT
Alight, Inc.
2.06+0.00
APYP
APPYEA, Inc.
0.01-0.00
AVAI
Avant Technologies Inc.
0.32+0.00
BFLY
Butterfly Network, Inc.
3.34+0.12
BWAY
Brainsway Ltd.
16.87-0.47
FLY
Firefly Aerospace Inc.
20.28-0.08
FYNN
Fyntechnical Innovations, Inc.
0.00+0.00
NMTC
NeuroOne Medical Technologies C
0.71+0.05
SNOW
Snowflake Inc.
220.60+5.32
WYFI
WhiteFiber, Inc.
15.08-0.13